

## Special Issue

# Immunotherapy in Triple Negative Breast Cancer

### Message from the Guest Editor

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, leading to poor prognosis and therapeutic response. Today, immunotherapy, such as immune checkpoint inhibitors (ICIs) and cell vaccine, is increasingly being used to treat TNBC patients. The biological function of immunotherapy in TNBC has resulted in durable clinical response and improved clinical outcomes. These findings have helped us to understand the importance of immune-response-based strategies for TNBC treatment. The aim of this Special Issue in the *Journal of Personalized Medicine* (JPM) is to highlight the current state of the report and showcase some of the latest findings in the field of immune-response-based strategies for TNBC patients. Manuscripts based on basic science, clinical, and population-based approaches are especially welcome.

### Guest Editor

Dr. Yuanliang Yan

Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China

### Deadline for manuscript submissions

closed (28 February 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/134967](https://mdpi.com/si/134967)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).